

—Mini Review—

Molecular mechanisms regulating embryo implantation in mammalsJunya Ito^{1,2,3*} and Naomi Kashiwazaki^{1,2}¹Laboratory of Animal Reproduction, Graduate School of Veterinary Science, Azabu University, Kanagawa 252-5201, Japan²School of Veterinary Medicine, Azabu University, Kanagawa 252-5201, Japan³Division of Reproductive Science, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 33342, USA

Abstract: In mammals, pregnancy is an irreversible and complicated event. The mammalian uterus requires many physiological and morphological changes for pregnancy-associated events including implantation, decidualization, placentation and parturition. The failure to complete any events results in implantation failure, spontaneous miscarriage or abnormal parturition, including preterm birth. These events are primarily regulated by ovarian estrogen and progesterone (P4). P4 and estrogen are produced in the ovary throughout pregnancy in mice, but in humans, hormonal support switches from the ovary to the placenta. The first direct interaction between embryo and uterus is implantation. In humans, about 75% of unsuccessful pregnancies are believed to result from defective implantation. Therefore, a better understanding of the molecular mechanisms associated with implantation would be helpful for the further improvement of clinical treatments. Recent studies using genetically modified mice have given us considerable insight into the molecular mechanisms underlying embryo implantation. In this review, we discuss in the understanding recent advances of the molecular events during implantation, especially focusing on the roles of estrogen and P4 signaling. We also offer our thoughts on the as yet unelucidated processes in implantation to guide and stimulate further research in this area.

Key words: Implantation, Pregnancy, Embryo, Uterus

Introduction

Human infertility has developed into serious physiological and social problems all over the world, especially in

developed countries. Numerous assisted reproductive technologies (ARTs), for example artificial insemination [1], *in vitro* fertilization (IVF) [2] and intracytoplasmic sperm injection (ICSI) [3], have been developed and are widely used for the rescue of human infertility. Also cryopreservation of sperm [4], oocytes [5], or embryos [6, 7] is an important technology which is routinely applied used by human infertility clinics. Despite the establishment of these technologies and great efforts by medical doctors, nurses and embryologists, current treatment methods cannot rescue the fertility of about half of couples who desire a baby. Therefore, additional research and improved knowledge of embryo implantation is required to develop new technologies to address these shortcomings.

In most mammalian species, oocytes are arrested at the metaphase-II stage before ovulation [7, 8]. Once oocytes have ovulated, they migrate to the oviductal ampulla, where fertilization occurs. Penetration of a sperm triggers the release of the metaphase-II arrest in oocytes via fertilization-associated calcium signaling [9–11]. Thereafter, the embryos transit to the uterus through the oviduct and then develop to the blastocyst stage. In the uterus, activation of extracellular regulated protein kinase occurs in the embryo giving it acquires the competence to be implanted in the uterine endometrium [12, 13]. The uterus undergoes considerable physiological and morphological changes during pregnancy. Successful pregnancy includes implantation, decidualization, placentation and parturition [12, 13]. The success of these events is indispensable for the birth of offspring. In humans, it is thought that 75% of unsuccessful pregnancies are associated with implantation failure [14], because implantation is the event of the first contact between the embryo and maternal tissue, and when implantation failure occurs, the subsequent pregnancy-associated events, such as




Fig. 1. Estrogen and progesterone (P4) orchestrate implantation window in mice. In mice, uterine sensitivity for accepting the embryo is composed from perceptible (Day 1–3; with the day of vaginal plug observed being defined as Day 1), receptive (Day 4) and refractory (Day 5 afternoon). On Day 4, an increase of estrogen level is observed prior to the receptive stage.

decidualization or placentation cannot take place [12, 13]. These pregnancy-associated events are primarily orchestrated by two steroid hormones called estrogen and progesterone (P4) [15]. Estrogen plays roles in the proliferation of epithelial cells, suppression of apoptosis, and regulation of the expression of lactoferrin and mucin 1 which are critical for normal uterine function [16–19]. On the other hand, P4 has roles in the suppression of epithelial cell proliferation and stromal cell proliferation via the expression of Indian hedgehog homolog (Ihh) and heart- and neural crest derivatives-expressed protein 2 (Hand2) [20–23]. Therefore, a better understanding of the molecular mechanisms associated with implantation would be helpful for the further improvement of clinical treatments. Recent studies using genetically modified mice have provided us with information for clarifying these molecular mechanisms. In this review, we provide an overview of the recent advances in our understanding about implantation, especially focusing on the roles of P4 and estrogen signaling.

A Theory of Implantation Window

In mice, uterine sensitivity for accepting the embryo is classified as perceptible (Day 1–3; with the day of vaginal plug observed being defined as Day 1), receptive (Day 4) and refractory (Day 5 afternoon) stages [12, 15] (See also in Fig. 1). Only during the receptive stage can embryos implant into the uterine epithelium. This duration of the receptive stage is also called the ‘implantation window’ [24]. Some research groups have demonstrated the start and end points of the implantation window using embryo

transfer in mice. Earlier studies showed that when embryos were transferred to the uterus at 9:00, 14:00 or 18:00 on Day 4, successful implantation was confirmed on Day 5 [25]. Another study showed that embryos transferred at 9:00 on Day 5 also implanted but not those transferred at 21:00 on the same day [26]. These results suggest the window of implantation opens at Day 4 and is maintained until the morning of Day 5. The transition from the pre-receptive to the receptive stage is primarily regulated by estrogen and progesterone (P4). Estrogen and P4 bind to their nuclear receptors at different times, and different cell-types in the uterus regulate the uterine receptivity of mammals [27, 28]. It is well known that two types of estrogen receptors ($ER\alpha$ and $ER\beta$) and two types of P4 receptors ($PR-A$ and $PR-B$ (*Pgr*)) are expressed in the mouse uterus. $ER\alpha$ -knockout mice show defective phenotypes during reproductive events, including implantation but not $ER\beta$ -knockout mice [29]. $PR-A$ and $PR-B$ double knockout mice are also infertile [30], but not single $PR-B$ knockout mice [31]. Based on these results, both $ER\alpha$ and $PR-A$ are essential for embryo implantation in mice. During ovulation, estrogen secreted from the ovary induces proliferation of uterine epithelial cells in the uterus [17]. In the epithelial-specific deletion of $ER\alpha$ in the mouse uterus, proliferation of epithelial cells and PR distribution was not affected [17], which suggests stromal $ER\alpha$ has a major role in these events. At the transition from the pre-receptive (Day 3) to receptive (Day 4) stage, a rise in P4 secretion occurs in the newly formed corpus lutea. Epithelial-specific deletion of PR cannot suppress the proliferation of epithelial cells by estrogen, suggesting that the role of PR in epithelial cells is to inhibit epithelial estrogen action for successful implantation [23].

On Day 4, a rise in the estrogen level derived from the ovary is observed prior to the receptive stage, but the detailed mechanism of this still remains unclear [32]. In several species other than mice, ovarian estrogen is dispensable for embryo implantation; however, ovarian P4 is indispensable for the process in all the species studied to date [12]. Ovariectomized mice on the morning of Day 4 (just prior to the rise of estrogen for implantation) can be used as a model of delayed implantation and embryonic dormancy [25]. Continuous P4 injection can maintain this condition for several days. Once estrogen is administered after P4 injection, implantation can be induced. These results suggest a rise in the level of estrogen is a key condition for the induction of embryo implantation. Using this model of delayed implantation, different concentrations of estrogen were examined. A high level of estrogen rapidly induced the transition to the refractory stage,

Estrogen signaling




Fig. 2. Estrogen-dependent signaling in epithelial and stromal cells during implantation. Estrogen binds to its nuclear receptor, ER α , in both epithelial and stromal cells. In the glandular epithelium, LIF expression occurs and binds to the receptor (LIFR and IL-6st) in the luminal epithelium, induces activation of Stat3. Activation of Stat3 is involved in stromal cell proliferation via growth factors expression. Stromal ER α is also important for cell proliferation of the luminal epithelium via activation of Fibroblast growth factors.

bypassing the receptive stage [25]. On the other hand, injection of low concentrations of estrogen did can eventually induce the transition to the receptive stage. These results strongly suggest that an optimal concentration of estrogen is required for on-time implantation.

The transition of these stages is one-way, and recovery from the refractory stage requires the withdrawal of P4 [12, 13]. Although a similar sequence of these events occurs in humans, the menstrual cycle is longer (around 28–30 days) than the estrus cycle in the mouse (around 4 days). Also in humans, it is known that the pre-receptive stage spans the first 7 days after ovulation (early luteal stage), and transition to the receptive stage occurs in the mid-luteal stage (around 7–10 days after ovulation). After that, the uterus proceeds to the refractory stage for the remainder of the cycle (late luteal stage), until menstruation ensues [13].

Role of Estrogen Signaling in Implantation

Although estrogen and P4 signaling are both essential for embryo implantation and their signaling are complicated, a major mediator of estrogen action is leukemia inhibitory factor (Lif) [33, 34] (See Fig. 2). Lif is a member of the interleukin-6 (IL-6) family of cytokines [35]. Deletion of the *Lif* gene causes complete implantation failure in mice, suggesting LIF is indispensable for embryo implantation [34]. Lif binds to its receptor (LifR) and IL-6

signal transducer (IL-6st), gp130 [35] (Fig. 2). At the time of implantation, both LifR and IL-6st are expressed in the uterine epithelium [36], and mice with deletion of LifR or IL-6st-knockout mice show embryonic lethality [37, 38]. Uterine deletion of IL-6st or its downstream target, signal transducer and activator of transcription 3 (Stat3), also causes implantation failure [39]. Recently, epithelium-specific deletion of Stat3 was shown to result in complete implantation failure followed by downregulation of epidermal growth factors (EGFs) which are essential for stromal cell proliferation [40]. In that study, it was also demonstrated that Stat3 has crucial roles for epithelial junctional reorganization via suppression of Claudin1, an integral membrane protein and a component of tight junction strands. On the other hand, stromal-specific deletion of Stat3 just decreased the number of pups due to defects in placentation followed by down-regulation of EGFs [41], suggesting the epithelial Lif-signaling pathway is important for implantation via activation of EGF signaling. In humans, it has been reported that a rise in Lif expression is seen before implantation [42] and some studies have demonstrated Lif expression is higher in fertile women than infertile women around the time of implantation [43, 44]. However, in other species except for mice, it remains inconclusive whether Lif is an indispensable factor for implantation.

A comparison of wild-type and *Lif*-null mice showed the homeobox transcription factor, *Msx1*, has an essen-

tial role during implantation [45–47]. *Msx1* is transiently expressed in the epithelium around the time of receptivity and its expression reached a maximal level on the morning of Day 4 [46], but it was not detected in the uteri of pregnant mice. Uterine specific deletion of *Msx1* resulted in partial implantation failure but double knockout of *Msx1* and *Msx2* (*Msx1/Msx2*), another member in the family, resulted in infertility due to complete implantation failure via suppression of bone morphogenetic protein 2 (*Bmp2*) and cyclooxygenase-2 (*Cox-2*) [46]. Since *Msx2* expression is upregulated in *Msx1* null, but not wild-type mice, *Msx2* has a compensatory role for *Msx1*. *Msx1/Msx2* are involved in the polarity of the luminal epithelium at the time of the attachment of embryos [46]. *Wnt5a*, a traditionally non-canonical Wnt and mediator of cell polarity, is upregulated in the epithelium and stroma of *Msx1/Msx2*-knockout mice [48]. A recent study revealed that downstream factors of *Wnt5a*, receptor tyrosine kinase-like orphan receptor 1 (*Ror1*) and *Ror2*, are essential for implantation and the disruption of *Wnt5a*-*Ror* signaling results in disorderly epithelial projections, crypt formation, embryo spacing and impaired implantation [49]. Another recent study showed that recombination signal binding protein for immunoglobulin kappa J region (*Rbbj*), the nuclear transducer of Notch signaling, confers on-time uterine lumen shape transformation by physically interacting with uterine ER α in a Notch pathway-independent manner [50]. These estrogen-dependent signaling pathways are required for normal mammalian embryo-uterus interaction.

Role of P4 in Implantation

The importance of P4 in implantation has been confirmed in all the mammalian species studied to date. Since a high P4 level is also required for later reproductive events, for example decidualization [51] and maintenance of pregnancy [52], P4 is called ‘the pregnancy hormone’. *PR* null mice show some defective phenotypes including disrupted ovulation, luteinization, and decidualization [30]. Epithelial-specific deletion of *PR* does not inhibit epithelial proliferation induced by estrogen, suggesting epithelial *PR* is essential for the suppression of estrogen action [23]. These *PR*-null mice also showed infertility in females which was attributed to incomplete uterine receptivity due to reduced expression of *Ihh*. It has been shown that *PR* can directly bind to *Ihh* promoter, resulting in the induction of the proliferation of stromal cells [23]. Another study showed stromal *PR* mediates induction of *Ihh* in the uterine epithelium and its downstream targets in the uterine stroma [53].

Chicken ovalbumin upstream promoter-transcription factor 2 (*COUP-TFII*) is a downstream target of *Ihh* signaling and it is expressed in the sub-epithelial stroma [54]. Uterine deletion of *COUP-TFII* causes implantation failure with excessive estrogenic action in the epithelium. A P4-induced transcription factor, *Hand2*, is expressed in the stroma and has been reported as a regulatory factor of uterine receptivity and implantation [22]. Uterine deletion of *Hand2* resulted in excessive estrogen activity and proliferation of epithelial cells via high expression of fibroblast growth factors (FGFs) [22]. These results suggest that a major role of *Hand2* in stromal cells is the suppression of epithelial proliferation. Another P4-inducible factor, *FKBP52*, is required for modulating *PR* activity [55–57]. *FKBP52* null mice show implantation failure due to impaired uterine P4 responsiveness and enhanced estrogen-like signaling. Deletion of *FKBP52* increases the sensitivity to oxidative stress followed by reduced expression of a unique antioxidant enzyme, peroxiredoxin 6 (*PRDX6*) [58]. However, since this type of infertility is rescued by the injection of antioxidants, it suggests that *FKBP52* has a partial role in implantation.

Conclusion

Studies of genetically modified mice have identified estrogen- or P4-dependent factors have been identified as critical factors involved in implantation in mammals. However, it is necessary to consider that most of the data previously reported was from knockout mice and the gene deletion was not specific to the uterus. For example, in most of these studies, *Pgr^{Cre}* transgenic mice (Cre recombinase is expressed under *Pgr* promoter) are used to generate uterine gene knockout mice [59]. *PR* is expressed not only in uterine cells but also in ovarian cells including the corpus luteum which is a source of P4 production. It has been shown that conditional deletion of the gene causes infertility due to its deletion not in the uterine tissues, but in other tissues [52]. In addition, *Wnt7a^{Cre}* and *Amhr2^{Cre}* transgenic mice are used for epithelial and stromal cell-specific deletion, respectively [17, 41]. These genes are potentially important for the development of the reproductive organs and Cre is expressed in developing female reproductive tracts, suggesting that the phenotype of infertility may be a secondary effect. Recently, *Lactoferrin-iCre (Ltf^{Cre})* transgenic mice have been developed [60]. In this line, Cre recombinase is first expressed in the uterine epithelium beyond day 30 after the birth. By using this new transgenic line, it may be able to more precisely clarify the molecular mechanisms underlying implantation.

Recently, genome editing technologies such as zinc-finger nuclease (ZFNs), transcription activator-like effector nucleases (TALENs), and CRISPR/Cas9 became available for the production of knockout animals [61–63]. Very recently, it has been shown that, at least in the mouse, these technologies are available for generating conditional knockout animals using genome editing technologies [64]. If these technologies were applied to the clarification of molecular mechanism of implantation in other mammalian species, the results from various species would help to explain species-dependent differences pregnancy-associated events.

Acknowledgments

We would like to thank the members of Laboratory of Animal Reproduction, School of Veterinary Medicine, Azabu University. We also want to thank Dr. Craig Park and Dr. Jumpei Terakawa for preparing the manuscript and helpful discussions. We apologize to the many researchers whose work has not been cited due to space limitations. This study was partially supported by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (JSPS) (KAKENHI, 24780272 to J.I.) and by a research project grant awarded by the Azabu University Research Services Division and International Exchange Committee of Azabu University to J.I.

References

- 1) ESHRE Capri Workshop Group (2009): Intrauterine insemination. *Hum. Reprod. Update* 15, 265–277.
- 2) Edwards, R.G. and Steptoe, P.C. (1983): Current status of in-vitro fertilisation and implantation of human embryos. *Lancet*, 322, 1265–1269. [[Medline](#)] [[CrossRef](#)]
- 3) Palermo, G., Joris, H., Devroey, P. and Van Steirteghem, A.C. (1992): Pregnancies after intracytoplasmic injection of single spermatozoon into an oocyte. *Lancet*, 340, 17–18. [[Medline](#)] [[CrossRef](#)]
- 4) Bunge, R.G. and Sherman, J.K. (1953): Fertilizing capacity of frozen human spermatozoa. *Nature*, 172, 767–768. [[Medline](#)] [[CrossRef](#)]
- 5) Chen, C. (1986): Pregnancy after human oocyte cryopreservation. *Lancet*, 327, 884–886. [[Medline](#)] [[CrossRef](#)]
- 6) Trounson, A. and Mohr, L. (1983): Human pregnancy following cryopreservation, thawing and transfer of an eight-cell embryo. *Nature*, 305, 707–709. [[Medline](#)] [[CrossRef](#)]
- 7) Richards, J.S. and Pangas, S.A. (2010): The ovary: basic biology and clinical implications. *J. Clin. Invest.*, 120, 963–972. [[Medline](#)] [[CrossRef](#)]
- 8) Coticchio, G., Dal Canto, M., Mignini Renzini, M., Guglielmo, M.C., Brambillasca, F., Turchi, D., Novara, P.V., and Fadini, R. (2015): Oocyte maturation: gamete-somatic cells interactions, meiotic resumption, cytoskeletal dynamics and cytoplasmic reorganization. *Hum. Reprod. Update*, (in press).
- 9) Ikawa, M., Inoue, N., Benham, A.M. and Okabe, M. (2010): Fertilization: a sperm's journey to and interaction with the oocyte. *J. Clin. Invest.*, 120, 984–994. [[Medline](#)] [[CrossRef](#)]
- 10) Ito, J., Parrington, J. and Fissore, R.A. (2011): PLC ζ and its role as a trigger of development in vertebrates. *Mol. Reprod. Dev.*, 78, 846–853. [[Medline](#)] [[CrossRef](#)]
- 11) Sato, K., Wakai, T., Seita, Y., Takizawa, A., Fissore, R.A., Ito, J. and Kashiwazaki, N. (2013): Molecular characteristics of horse phospholipase C zeta (PLC ζ). *Anim. Sci. J.*, 84, 359–368. [[Medline](#)] [[CrossRef](#)]
- 12) Wang, H. and Dey, S.K. (2006): Roadmap to embryo implantation: clues from mouse models. *Nat. Rev. Genet.*, 7, 185–199. [[Medline](#)] [[CrossRef](#)]
- 13) Cha, J., Sun, X. and Dey, S.K. (2012): Mechanisms of implantation: strategies for successful pregnancy. *Nat. Med.*, 18, 1754–1767. [[Medline](#)] [[CrossRef](#)]
- 14) Norwitz, E.R., Schust, D.J. and Fisher, S.J. (2001): Implantation and the survival of early pregnancy. *N. Engl. J. Med.*, 345, 1400–1408. [[Medline](#)] [[CrossRef](#)]
- 15) Dey, S.K., Lim, H., Das, S.K., Reese, J., Paria, B.C., Dairaku, T. and Wang, H. (2004): Molecular cues to implantation. *Endocr. Rev.*, 25, 341–373. [[Medline](#)] [[CrossRef](#)]
- 16) Hewitt, S.C., Deroo, B.J., Hansen, K., Collins, J., Grissom, S., Afshari, C.A. and Korach, K.S. (2003): Estrogen receptor-dependent genomic responses in the uterus mirror the biphasic physiological response to estrogen. *Mol. Endocrinol.*, 17, 2070–2083. [[Medline](#)] [[CrossRef](#)]
- 17) Winuthayanon, W., Hewitt, S.C., Orvis, G.D., Behringer, R.R. and Korach, K.S. (2010): Uterine epithelial estrogen receptor α is dispensable for proliferation but essential for complete biological and biochemical responses. *Proc. Natl. Acad. Sci. USA*, 107, 19272–19277. [[Medline](#)] [[CrossRef](#)]
- 18) Teng, C.T. (2002): Lactoferrin gene expression and regulation: an overview. *Biochem. Cell Biol.*, 80, 7–16. [[Medline](#)] [[CrossRef](#)]
- 19) Surveyor, G.A., Gendler, S.J., Pemberton, L., Das, S.K., Chakraborty, I., Julian, J., Pimental, R.A., Wegner, C.C., Dey, S.K. and Carson, D.D. (1995): Expression and steroid hormonal control of Muc-1 in the mouse uterus. *Endocrinology*, 136, 3639–3647. [[Medline](#)]
- 20) Lee, K., Jeong, J., Kwak, I., Yu, C.T., Lanske, B., Soegiarto, D.W., Toftgard, R., Tsai, M.J., Tsai, S., Lydon, J.P. and DeMayo, F.J. (2006): Indian hedgehog is a major mediator of progesterone signaling in the mouse uterus. *Nat. Genet.*, 38, 1204–1209. [[Medline](#)] [[CrossRef](#)]
- 21) Matsumoto, H., Zhao, X., Das, S.K., Hogan, B.L. and Dey, S.K. (2002): Indian hedgehog as a progesterone-responsive factor mediating epithelial-mesenchymal interactions in the mouse uterus. *Dev. Biol.*, 245, 280–290. [[Medline](#)] [[CrossRef](#)]
- 22) Li, Q., Kannan, A., DeMayo, F.J., Lydon, J.P., Cooke, P.S., Yamagishi, H., Srivastava, D., Bagchi, M.K. and Bagchi, I.C. (2011): The antiproliferative action of progesterone in uterine epithelium is mediated by Hand2. *Science*, 331, 912–916. [[Medline](#)] [[CrossRef](#)]

- 23) Franco, H.L., Rubel, C.A., Large, M.J., Wetendorf, M., Fernandez-Valdivia, R., Jeong, J.W., Spencer, T.E., Behringer, R.R., Lydon, J.P. and Demayo, F.J. (2012): Epithelial progesterone receptor exhibits pleiotropic roles in uterine development and function. *FASEB J.*, 26, 1218–1227. [[Medline](#)] [[CrossRef](#)]
- 24) Psychoyos, A. (1973): *Endocrine Control of Egg Implantation* (American Physiology Society, Washington, D.C.).
- 25) Paria, B.C., Huet-Hudson, Y.M. and Dey, S.K. (1993): Blastocyst's state of activity determines the "window" of implantation in the receptive mouse uterus. *Proc. Natl. Acad. Sci. USA*, 90, 10159–10162. [[Medline](#)] [[CrossRef](#)]
- 26) Song, H., Han, K. and Lim, H. (2007): Progesterone supplementation extends uterine receptivity for blastocyst implantation in mice. *Reproduction*, 133, 487–493. [[Medline](#)] [[CrossRef](#)]
- 27) Tranguch, S., Smith, D.F. and Dey, S.K. (2007): Progesterone receptor requires a co-chaperone for signalling in uterine biology and implantation. *Reprod. Biomed. Online*, 14, 39–48. [[Medline](#)]
- 28) Pawar, S., Hantak, A.M., Bagchi, I.C. and Bagchi, M.K. (2014): Minireview: Steroid-regulated paracrine mechanisms controlling implantation. *Mol. Endocrinol.*, 28, 1408–1422. [[Medline](#)] [[CrossRef](#)]
- 29) Lubahn, D.B., Moyer, J.S., Golding, T.S., Couse, J.F., Korach, K.S. and Smithies, O. (1993): Alteration of reproductive function but not prenatal sexual development after interstitial disruption of the mouse estrogen receptor gene. *Proc. Natl. Acad. Sci. USA*, 90, 11162–11166. [[Medline](#)] [[CrossRef](#)]
- 30) Lydon, J.P., DeMayo, F.J., Funk, C.R., Mani, S.K., Hughes, A.R., Montgomery, C.A. Jr., Shyamala, G., Conneely, O.M. and O'Malley, B.W. (1995): Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. *Genes Dev.*, 9, 2266–2278. [[Medline](#)] [[CrossRef](#)]
- 31) Mulac-Jericevic, B., Mullinax, R.A., DeMayo, F.J., Lydon, J.P. and Conneely, O.M. (2000): Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform. *Science*, 289, 1751–1754. [[Medline](#)] [[CrossRef](#)]
- 32) Thomas, K., De Hertogh, R., Pizarro, M., Van Exter, C. and Ferin, J. (1973): Plasma LH-HCG, 17-estradiol, estrone and progesterone monitoring around ovulation and subsequent nidation. *Int. J. Fertil.*, 18, 65–73. [[Medline](#)]
- 33) Song, H., Lim, H., Das, S.K., Paria, B.C. and Dey, S.K. (2000): Dysregulation of EGF family of growth factors and COX-2 in the uterus during the preattachment and attachment reactions of the blastocyst with the luminal epithelium correlates with implantation failure in LIF-deficient mice. *Mol. Endocrinol.*, 14, 1147–1161. [[Medline](#)] [[CrossRef](#)]
- 34) Stewart, C.L., Kaspar, P., Brunet, L.J., Bhatt, H., Gadi, I., Köntgen, F. and Abbondanzo, S.J. (1992): Blastocyst implantation depends on maternal expression of leukaemia inhibitory factor. *Nature*, 359, 76–79. [[Medline](#)] [[CrossRef](#)]
- 35) Kishimoto, T. (2005): Interleukin-6: from basic science to medicine—40 years in immunology. *Annu. Rev. Immunol.*, 23, 1–21. [[Medline](#)] [[CrossRef](#)]
- 36) Song, H. and Lim, H. (2006): Evidence for heterodimeric association of leukemia inhibitory factor (LIF) receptor and gp130 in the mouse uterus for LIF signaling during blastocyst implantation. *Reproduction*, 131, 341–349. [[Medline](#)] [[CrossRef](#)]
- 37) Ware, C.B., Horowitz, M.C., Renshaw, B.R., Hunt, J.S., Liggitt, D., Koblar, S.A., Gliniak, B.C., McKenna, H.J., Papayannopoulou, T., Thoma, B., Cheng, L., Donovan, P.J., Peschon, J.J., Bartlitt, P.F., Wills, C.R., Wright, B.D., Carpenter, M.K., Davison, B.L. and Gearing, D.P. (1995): Targeted disruption of the low-affinity leukemia inhibitory factor receptor gene causes placental, skeletal, neural and metabolic defects and results in perinatal death. *Development*, 121, 1283–1299. [[Medline](#)]
- 38) Yoshida, K., Taga, T., Saito, M., Suematsu, S., Kumanogoh, A., Tanaka, T., Fujiwara, H., Hirata, M., Yamagami, T., Nakahata, T., Hirabayashi, T., Yoneda, Y., Tanaka, K., Wang, W.Z., Mori, C., Shiota, K., Yoshida, N. and Kishimoto, T. (1996): Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. *Proc. Natl. Acad. Sci. USA*, 93, 407–411. [[Medline](#)] [[CrossRef](#)]
- 39) Sun, X., Bartos, A., Whitsett, J.A. and Dey, S.K. (2013): Uterine deletion of Gp130 or Stat3 shows implantation failure with increased estrogenic responses. *Mol. Endocrinol.*, 27, 1492–1501. [[Medline](#)] [[CrossRef](#)]
- 40) Pawar, S., Starosvetsky, E., Orvis, G.D., Behringer, R.R., Bagchi, I.C. and Bagchi, M.K. (2013): STAT3 regulates uterine epithelial remodeling and epithelial-stromal crosstalk during implantation. *Mol. Endocrinol.*, 27, 1996–2012. [[Medline](#)] [[CrossRef](#)]
- 41) Robker, R.L., Watson, L.N., Robertson, S.A., Dunning, K.R., McLaughlin, E.A. and Russell, D.L. (2014): Identification of sites of STAT3 action in the female reproductive tract through conditional gene deletion. *PLoS ONE*, 9, e101182. [[Medline](#)] [[CrossRef](#)]
- 42) Laird, S.M., Tuckerman, E.M., Dalton, C.F., Dunphy, B.C., Li, T.C. and Zhang, X. (1997): The production of leukaemia inhibitory factor by human endometrium: presence in uterine flushings and production by cells in culture. *Hum. Reprod.*, 12, 569–574. [[Medline](#)] [[CrossRef](#)]
- 43) Piccinni, M.P., Beloni, L., Livi, C., Maggi, E., Scarselli, G. and Romagnani, S. (1998): Defective production of both leukemia inhibitory factor and type 2 T-helper cytokines by decidual T cells in unexplained recurrent abortions. *Nat. Med.*, 4, 1020–1024. [[Medline](#)] [[CrossRef](#)]
- 44) Hambartsoomian, E. (1998): Endometrial leukemia inhibitory factor (LIF) as a possible cause of unexplained infertility and multiple failures of implantation. *Am. J. Reprod. Immunol.*, 39, 137–143. [[Medline](#)] [[CrossRef](#)]
- 45) Daikoku, T., Song, H., Guo, Y., Riesewijk, A., Mosselman, S., Das, S.K. and Dey, S.K. (2004): Uterine Msx-1 and Wnt4 signaling becomes aberrant in mice with the loss of leukemia inhibitory factor or Hoxa-10: evidence for a novel cytokine-homeobox-Wnt signaling in implantation. *Mol. Endocrinol.*, 18, 1238–1250. [[Medline](#)] [[CrossRef](#)]
- 46) Daikoku, T., Cha, J., Sun, X., Tranguch, S., Xie, H., Fujita, T., Hirota, Y., Lydon, J., DeMayo, F., Maxson, R. and Dey, S.K. (2011): Conditional deletion of Msx homeobox genes in

- the uterus inhibits blastocyst implantation by altering uterine receptivity. *Dev. Cell*, 21, 1014–1025. [[Medline](#)] [[CrossRef](#)]
- 47) Nallasamy, S., Li, Q., Bagchi, M.K. and Bagchi, I.C. (2012): Msx homeobox genes critically regulate embryo implantation by controlling paracrine signaling between uterine stroma and epithelium. *PLoS Genet.*, 8, e1002500. [[Medline](#)] [[CrossRef](#)]
 - 48) Cha, J., Sun, X., Bartos, A., Fenelon, J., Lefèvre, P., Daikoku, T., Shaw, G., Maxson, R., Murphy, B.D., Renfree, M.B. and Dey, S.K. (2013): A new role for muscle segment homeobox genes in mammalian embryonic diapause. *Open Biol.*, 3, 130035. [[Medline](#)] [[CrossRef](#)]
 - 49) Cha, J., Bartos, A., Park, C., Sun, X., Li, Y., Cha, S.W., Ajima, R., Ho, H.Y., Yamaguchi, T.P. and Dey, S.K. (2014): Appropriate crypt formation in the uterus for embryo homing and implantation requires Wnt5a-ROR signaling. *Cell Reports*, 8, 382–392. [[Medline](#)] [[CrossRef](#)]
 - 50) Zhang, S., Kong, S., Wang, B., Cheng, X., Chen, Y., Wu, W., Wang, Q., Shi, J., Zhang, Y., Wang, S., Lu, J., Lydon, J.P., DeMayo, F., Pear, W.S., Han, H., Lin, H., Li, L., Wang, H., Wang, Y.L., Li, B., Chen, Q., Duan, E. and Wang, H. (2014): Uterine Rbpj is required for embryonic-uterine orientation and decidual remodeling via Notch pathway-independent and -dependent mechanisms. *Cell Res.*, 24, 925–942. [[Medline](#)] [[CrossRef](#)]
 - 51) Large, M.J. and DeMayo, F.J. (2012): The regulation of embryo implantation and endometrial decidualization by progesterone receptor signaling. *Mol. Cell. Endocrinol.*, 358, 155–165. [[Medline](#)] [[CrossRef](#)]
 - 52) Sun, X., Terakawa, J., Clevers, H., Barker, N., Daikoku, T. and Dey, S.K. (2014): Ovarian LGR5 is critical for successful pregnancy. *FASEB J.*, 28, 2380–2389. [[Medline](#)] [[CrossRef](#)]
 - 53) Simon, L., Spiewak, K.A., Ekman, G.C., Kim, J., Lydon, J.P., Bagchi, M.K., Bagchi, I.C., DeMayo, F.J. and Cooke, P.S. (2009): Stromal progesterone receptors mediate induction of Indian Hedgehog (IHH) in uterine epithelium and its downstream targets in uterine stroma. *Endocrinology*, 150, 3871–3876. [[Medline](#)] [[CrossRef](#)]
 - 54) Kurihara, I., Lee, D.K., Petit, F.G., Jeong, J., Lee, K., Lydon, J.P., DeMayo, F.J., Tsai, M.J. and Tsai, S.Y. (2007): COUP-TFII mediates progesterone regulation of uterine implantation by controlling ER activity. *PLoS Genet.*, 3, e102. [[Medline](#)] [[CrossRef](#)]
 - 55) Tranguch, S., Wang, H., Daikoku, T., Xie, H., Smith, D.F. and Dey, S.K. (2007): FKBP52 deficiency-conferred uterine progesterone resistance is genetic background and pregnancy stage specific. *J. Clin. Invest.*, 117, 1824–1834. [[Medline](#)] [[CrossRef](#)]
 - 56) Tranguch, S., Cheung-Flynn, J., Daikoku, T., Prapapanich, V., Cox, M.B., Xie, H., Wang, H., Das, S.K., Smith, D.F. and Dey, S.K. (2005): Cochaperone immunophilin FKBP52 is critical to uterine receptivity for embryo implantation. *Proc. Natl. Acad. Sci. USA*, 102, 14326–14331. [[Medline](#)] [[CrossRef](#)]
 - 57) Hiraoka, T., Fujita-Saito, T. and Hirota, Y. How does progesterone support rmbryo implantation? *J. Mamm. Ova Res.* (in press).
 - 58) Hirota, Y., Acar, N., Tranguch, S., Burnum, K.E., Xie, H., Kodama, A., Osuga, Y., Ustunel, I., Friedman, D.B., Caprioli, R.M., Daikoku, T. and Dey, S.K. (2010): Uterine FK506-binding protein 52 (FKBP52)-peroxiredoxin-6 (PRDX6) signaling protects pregnancy from overt oxidative stress. *Proc. Natl. Acad. Sci. USA*, 107, 15577–15582. [[Medline](#)] [[CrossRef](#)]
 - 59) Soyal, S.M., Mukherjee, A., Lee, K.Y., Li, J., Li, H., DeMayo, F.J. and Lydon, J.P. (2005): Cre-mediated recombination in cell lineages that express the progesterone receptor. *Genesis*, 41, 58–66. [[Medline](#)] [[CrossRef](#)]
 - 60) Daikoku, T., Ogawa, Y., Terakawa, J., Ogawa, A., DeFalco, T. and Dey, S.K. (2014): Lactoferrin-iCre: a new mouse line to study uterine epithelial gene function. *Endocrinology*, 155, 2718–2724. [[Medline](#)] [[CrossRef](#)]
 - 61) Geurts, A.M., Cost, G.J., Freyvert, Y., Zeitler, B., Miller, J.C., Choi, V.M., Jenkins, S.S., Wood, A., Cui, X., Meng, X., Vincent, A., Lam, S., Michalkiewicz, M., Schilling, R., Foeckler, J., Kalloway, S., Weiler, H., Ménoret, S., Anegón, I., Davis, G.D., Zhang, L., Rebar, E.J., Gregory, P.D., Urnov, F.D., Jacob, H.J. and Buelow, R. (2009): Knockout rats via embryo microinjection of zinc-finger nucleases. *Science*, 325, 433. [[Medline](#)] [[CrossRef](#)]
 - 62) Joung, J.K. and Sander, J.D. (2013): TALENs: a widely applicable technology for targeted genome editing. *Nat. Rev. Mol. Cell Biol.*, 14, 49–55. [[Medline](#)] [[CrossRef](#)]
 - 63) Wang, H., Yang, H., Shivalila, C.S., Dawlaty, M.M., Cheng, A.W., Zhang, F. and Jaenisch, R. (2013): One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. *Cell*, 153, 910–918. [[Medline](#)] [[CrossRef](#)]
 - 64) Platt, R.J., Chen, S., Zhou, Y., Yim, M.J., Swiech, L., Kempton, H.R., Dahlman, J.E., Parnas, O., Eisenhaure, T.M., Ivanovic, M., Graham, D.B., Jhunjunwala, S., Heidenreich, M., Xavier, R.J., Langer, R., Anderson, D.G., Hacohen, N., Regev, A., Feng, G., Sharp, P.A. and Zhang, F. (2014): CRISPR-Cas9 knockin mice for genome editing and cancer modeling. *Cell*, 159, 440–455. [[Medline](#)] [[CrossRef](#)]